Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Vaccines Comprising Sand Fly Salivary Proteins for Control of Leishmania Infection
Case ID:
TAB-787
Web Published:
12/6/2022
This invention relates to the use of several peptides from the salivary glands of various sand fly species for the control of leishmania infection. Many of these peptides were shown to be effective in eliciting potent immune responses in animal models and are excellent candidates for the development of vaccines against the disease. A vaccine comprising one of the peptides was used to protect mice challenged with parasites and salivary gland homogenates. A DNA vaccine containing the cDNA for this same peptide also provided protection that lasted at least 3 months after immunization and produced both intense humoral and delayed-type hypersensitivity reactions. Other experiments have shown that B cell-deficient mice immunized with the plasmid vaccine also successfully controlled leishmania infection. Current
in-vivo
studies continue to explore the use of these sand fly salivary peptides for use as animal vaccines.
Leishmania parasites are transmitted to their vertebrate hosts by infected sand fly bites. Sand fly saliva helps to enhance infection but immunity to the saliva protects against the infection, allowing the possibility of vaccine development. A number of major salivary proteins from sand fly species such as
Lutzomyia longipalpis
,
Phlebotomus ariasi
, and
Phlebotomus perniciosus
are claimed in the invention.
Leishmania infection affects as many as 12 million people worldwide, with 1.5-2 million new cases each year. Control of this disease will be a major milestone for public health efforts in endemic areas of the world. The current invention provides a potential means to achieve widespread vaccination that may lead to significantly control of the disease in areas such as South America, South Asia, and the Mediterranean where it is still a significant health problem. An effective veterinary vaccine will be of benefit to veterinary medicine and may pave the way for human vaccines against Leishmaniasis. The vaccination of animals may also have a positive impact on the epidemiology of the disease by reducing the number of animal reservoirs and the possibility of human infection.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Vaccines_Comprising_Sand_Fly _Salivary_Proteins_for_Control_of_Leishmania_Infection
Keywords:
Adn
America
ARIASI
Cellular
Chagase
DA2XXX
DAXXXX
DB2XXX
DBXXXX
DC2XXX
DCXXXX
DDXXXX
Dogs
DXXXXX
Efficient
ELICIT
Fly
Identification
IFN-gamma
Immunity
Infantum
KILLING
Latin
LEISHMANIA
LEISHMANIASIS
Leishmaniasis (Leishmania sp.)
Listed LPM Stansberry as of 4/15/2015
LJL143
LJM17
Longipalpis
Lutzomyiz
Method
P.
Patent Category - Biotechnology
PERNICIOSUS
POLYPEPTIDES
Post LPM Assignment Set 20150420
Pre LPM working set 20150418
production
proteins
RESULTING
Salivary
SAND
That
Vector
Visceral
WIPO Re:search
Bookmark this page
Download as PDF
For Information, Contact:
Peter Tung
Technology Development Specialist
NIH Technology Transfer
240-669-5483
peter.tung@nih.gov